Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lynparza | Olaparib | metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Remsima | infliximab | Rheumatoid arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inqovi | Decitabine-Cedazuridine | Myelodysplastic Syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Alunbrig | Brigatinib | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar and Mekinist | Dabrafenib and Trametinib | NSCLC BRAF V600 | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 9, 2024